A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)
J
John Strobel, MD
Primary Investigator
Administratively Closed
18 years or above
All
Phase
3
15500 participants needed
1 Location
Brief description of study
The purpose of this study is to evaluate if milvexian is at least as effective as apixabanducing the risk of the composite stroke and non- central nervous system (CNS) systemicbolism.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Atrial Fibrillation
-
Age: 18 years or above
-
Gender: All
Inclusion Criteria:
- Minimum age of 18 years
- Medically stable and appropriate for chronic antithrombotic treatment
- Atrial fibrillation eligible to receive anticoagulation
- Participant must satisfy one or both of the following categories of risk factors (a orb): a) one or more of the following risk factors: i) age greater than or equal to 75years, ii) history of a clinical symptomatic stroke. b) two or more of the followingk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetesus, iv) atherosclerotic vascular disease, v) heart failure
Exclusion Criteria:
- Hemodynamically significant valve disease or those with valve disease that willy require surgical valve replacement during the study
- Any condition other than AF that requires chronic anticoagulation
Updated on
08 Apr 2025.
Study ID: BLOOM-JANSSEN-LIBREXIA-AF, CR109220, 18926
